Oncobiologics (OTLK) to Release Quarterly Earnings on Wednesday

Key Points

• Oncobiologics is expected to announce its Q3 2025 earnings on August 13th, with analysts predicting an EPS of ($0.42) and revenue of $1.66 million.
• In its last earnings report on May 15th, Oncobiologics reported an EPS of ($0.40), beating expectations by $0.15.
• A Goldman Sachs Group Inc. increased its stake in Oncobiologics by 74.1%, reflecting growing institutional interest in the company.

Oncobiologics (NASDAQ:OTLK - Get Free Report) will likely be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect Oncobiologics to post earnings of ($0.42) per share and revenue of $1.66 million for the quarter.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.15. On average, analysts expect Oncobiologics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Stock Performance

NASDAQ:OTLK traded down $0.04 on Thursday, hitting $1.84. 815,164 shares of the stock were exchanged, compared to its average volume of 919,962. The company's 50-day moving average price is $1.90 and its 200 day moving average price is $1.69. The stock has a market capitalization of $61.77 million, a price-to-earnings ratio of -2.02 and a beta of 0.26. Oncobiologics has a 52 week low of $0.87 and a 52 week high of $8.32.

Wall Street Analysts Forecast Growth

OTLK has been the subject of a number of recent research reports. Ascendiant Capital Markets reduced their price objective on shares of Oncobiologics from $24.00 to $21.00 and set a "buy" rating for the company in a research note on Friday, June 6th. Guggenheim reissued a "buy" rating on shares of Oncobiologics in a report on Tuesday, May 20th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.60.

Institutional Investors Weigh In On Oncobiologics

A hedge fund recently raised its stake in Oncobiologics stock. AQR Capital Management LLC raised its stake in shares of Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) by 42.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,671 shares of the company's stock after buying an additional 25,351 shares during the period. AQR Capital Management LLC owned about 0.26% of Oncobiologics worth $103,000 as of its most recent SEC filing. 11.20% of the stock is currently owned by institutional investors.

About Oncobiologics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.